Humana (HUM) to Cover Sarepta (SRPT)'s Controversial DMD Drug But There's a Catch 10/27/2016
The FDA's controversial approval of Sarepta Therapeutics' (NASDAQ:SRPT) eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping has translated into a difficult path to insurance coverage.
Humana says it will cover the $300K+ cost of therapy only for ambulatory DMD patients. Those who are wheelchair-bound or deteriorate to wheelchair status are apparently out of luck.
Anthem (NYSE:ANTM) has declined to cover it at all because it considers eteplirsen experimental despite the OK from the FDA.
Humana (HUM) to Cover Sarepta (SRPT)'s Controversial DMD Drug But There's a Catch
ReplyDelete10/27/2016
The FDA's controversial approval of Sarepta Therapeutics' (NASDAQ:SRPT) eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping has translated into a difficult path to insurance coverage.
Humana says it will cover the $300K+ cost of therapy only for ambulatory DMD patients. Those who are wheelchair-bound or deteriorate to wheelchair status are apparently out of luck.
Anthem (NYSE:ANTM) has declined to cover it at all because it considers eteplirsen experimental despite the OK from the FDA.
http://www.biospace.com/News/humana-to-cover-sareptas-controversial-dmd-drug/437013/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
Picking winners and losers in treatment....healthcare/compassion at it's finest...the system sucks. Should happen to their kids.